CN112023019A - Medicine containing active polysaccharide with effect of reducing uric acid and preparation method thereof - Google Patents

Medicine containing active polysaccharide with effect of reducing uric acid and preparation method thereof Download PDF

Info

Publication number
CN112023019A
CN112023019A CN202010970484.8A CN202010970484A CN112023019A CN 112023019 A CN112023019 A CN 112023019A CN 202010970484 A CN202010970484 A CN 202010970484A CN 112023019 A CN112023019 A CN 112023019A
Authority
CN
China
Prior art keywords
parts
powder
vitamin
active polysaccharide
uric acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010970484.8A
Other languages
Chinese (zh)
Inventor
李婷婷
费韶翔
于国阳
孙纪新
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai University of Medicine and Health Sciences
Original Assignee
Shanghai University of Medicine and Health Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai University of Medicine and Health Sciences filed Critical Shanghai University of Medicine and Health Sciences
Priority to CN202010970484.8A priority Critical patent/CN112023019A/en
Publication of CN112023019A publication Critical patent/CN112023019A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L13/00—Meat products; Meat meal; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
    • A23L7/10—Cereal-derived products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/58—Reptiles
    • A61K35/583—Snakes; Lizards, e.g. chameleons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/732—Chaenomeles, e.g. flowering quince
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A61K36/8994—Coix (Job's tears)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention discloses an active polysaccharide-containing medicament with the effect of reducing uric acid and a preparation method thereof, wherein the active polysaccharide-containing medicament comprises the following components in parts by weight: 8-15 parts of marine fish oligopeptide powder, 5-12 parts of taxus chinensis polysaccharide, 7-15 parts of pawpaw, 6-11 parts of pit viper, 7-13 parts of coix seed, 11-20 parts of celery powder, 11-19 parts of burdock root powder, 1-15 parts of corn stigma powder, 3-16 parts of egg white chlorella powder, 6-19 parts of vitamin, 11-30 parts of edible auxiliary material and 5-15 parts of phellinus igniarius. The active polysaccharide-containing medicament has synergistic effect of the raw materials and obvious effect of reducing uric acid.

Description

Medicine containing active polysaccharide with effect of reducing uric acid and preparation method thereof
Technical Field
The invention relates to the technical field of medicines, in particular to a medicine containing active polysaccharide and having the function of reducing uric acid and a preparation method thereof.
Background
Uric acid is a final product of purine metabolism in a human body, the daily production amount and the excretion amount of uric acid in the human body are approximately equal, but the uric acid content is increased when purine metabolism in the human body is disturbed, and because the solubility of uric acid is low, urinary calculus or gout can be formed when the uric acid is excessive in the human body. Hyperuricemia is a state of the body in which the uric acid concentration in blood is out of the normal range, and it is generally considered that hyperuricemia is considered when the uric acid concentration in blood of a male is more than 400. mu. mol/L and when the uric acid concentration in blood of a female is more than 360. mu. mol/L. Recent studies have shown that hyperuricemia is not only the most important biochemical basis of gout, but also an important factor causing hypertension, hyperlipidemia, atherosclerosis, obesity, insulin resistance, occurrence of cardiovascular diseases of metabolic syndrome and death, and has become one of the major metabolic diseases threatening human health.
The current clinical commonly used medicines comprise nonsteroidal anti-inflammatory drugs, colchicine, glucocorticoid, probenecid, benzydomone and allopurinol, and the treatment effect is obvious, but the medicines have toxic and side effects and adverse reactions of different degrees, damage the liver and the nervous system, cause skin allergy, life-threatening hypersensitivity and the like.
Disclosure of Invention
The invention aims to provide an active polysaccharide-containing medicament with the effect of reducing uric acid and a preparation method thereof aiming at the defects in the prior art.
In order to achieve the purpose, the invention adopts the technical scheme that:
the invention provides an active polysaccharide-containing medicament with the effect of reducing uric acid, which comprises the following components in parts by weight: 8-15 parts of marine fish oligopeptide powder, 5-12 parts of taxus chinensis polysaccharide, 7-15 parts of pawpaw, 6-11 parts of pit viper, 7-13 parts of coix seed, 11-20 parts of celery powder, 11-19 parts of burdock root powder, 1-15 parts of corn stigma powder, 3-16 parts of egg white chlorella powder, 6-19 parts of vitamin, 11-30 parts of edible auxiliary material and 5-15 parts of phellinus igniarius.
Preferably, the active polysaccharide-containing medicament comprises the following components in parts by weight: 10-13 parts of marine fish oligopeptide powder, 7-10 parts of taxus chinensis polysaccharide, 9-14 parts of pawpaw, 8-10 parts of pit viper, 8-11 parts of coix seed, 17-20 parts of celery powder, 16-18 parts of burdock root powder, 13-15 parts of corn stigma powder, 14-16 parts of chlorella pyrenoidosa powder, 10-15 parts of vitamin, 12-29 parts of edible auxiliary materials and 8-12 parts of phellinus igniarius.
Preferably, the vitamin is one or more of vitamin A, vitamin D, vitamin E, vitamin C, vitamin B1, vitamin B2, vitamin B6, vitamin B12, nicotinic acid, folic acid, pantothenic acid, choline and nicotinamide.
Preferably, the edible auxiliary materials are one or more of excipient, stabilizer, flavoring agent and color fixative.
The second aspect of the invention provides a preparation method of the active polysaccharide-containing medicament, which comprises the following steps:
s1, weighing the pawpaw and the pit viper according to the weight parts, adding 12-15 times of water, heating and extracting for several times, filtering, combining the filtrates, and concentrating the filtrate to a clear paste with the relative density of 1.2-1.4 measured at 65-75 ℃; weighing the coix seeds according to the parts by weight, crushing the coix seeds into fine powder, and sieving the fine powder by a sieve of 60-90 meshes;
s2, weighing the marine fish oligopeptide powder, the taxus chinensis polysaccharide, the celery powder, the burdock root powder, the corn stigma powder, the globulina powder, the vitamins, the edible auxiliary materials and the phellinus igniarius according to the parts by weight, adding the clear paste prepared in the step S1 and the coix seed powder, and uniformly mixing to prepare the active polysaccharide-containing pharmaceutical preparation.
Preferably, in S1, the heating is performed for 2-3 times, each for 2-3 hours.
Preferably, in S2, the active polysaccharide-containing pharmaceutical preparation is in the form of a tablet, capsule, powder, pill or granule.
The third aspect of the invention provides the application of the medicine containing active polysaccharide in preparing health products, foods or medicines with the effect of reducing uric acid.
By adopting the technical scheme, compared with the prior art, the invention has the following technical effects:
1. the Chinese yew polysaccharide has excellent effect of reducing uric acid and creatinine thereof, has a protection effect on kidney, and has an obvious uric acid reducing effect in clinical experiments when a medicament prepared by using the Chinese yew polysaccharide as an active ingredient. The ocean fish oligopeptide powder has the functions of reducing uric acid and relieving gout; the muscle exercise time is prolonged, and the muscle exercise intensity is increased; the inflammation phenomenon is reduced; reducing gastric ulcer symptoms and accelerating wound healing; relieving muscle aging weakness symptoms; enhancing the conduction velocity of the neural response; reduce myocardial ischemia and cerebral ischemia injury.
2. The pawpaw in the invention is a dry nearly mature fruit of chaenomeles speciosa belonging to the Rosaceae family, and has the functions of relaxing tendons, activating collaterals, harmonizing stomach and eliminating dampness; has obvious effect on treating symptoms such as damp arthralgia spasm, soreness and heaviness pain of waist and knee joints, spasm pain of rotating muscles, beriberi edema and the like. Agkistrodon Halys is dried whole body of Viperaceae animal with viscera removed, and has effects of dispelling pathogenic wind, relieving pain, removing toxic substance, strengthening body, and promoting lactation; it can be used for treating rheumatalgia, leprosy, lymph node, tuberculosis, skin ulcer, furuncle, asthenia, hyperhidrosis, and milk deficiency. Coicis semen is dried mature seed of Gramineae plant Coicis semen, and has effects of promoting diuresis, eliminating dampness, invigorating spleen, relieving diarrhea, eliminating arthralgia, promoting pus, removing toxic substance and resolving hard mass; can be used for treating edema, loempe, dysuresia, spleen deficiency, diarrhea, damp arthralgia, spasm, pulmonary abscess, intestinal abscess, wart, and cancer.
3. The celery powder, the burdock root powder, the corn stigma powder and the globulina powder are combined to be used as raw materials; wherein the celery powder is cool in nature, sweet and pungent in taste and nontoxic; entering liver, gallbladder and pericardium channel; mainly used for clearing heat, calming liver, relieving restlessness, dispelling wind, promoting diuresis and reducing edema. The bitter and cold burdock root powder is matched to dispel wind-heat and eliminate swelling and toxin; bitter and cold can purge and purge the pathogenic wind and dampness to calm the stomach-qi and purge the heat. The corn stigma powder is sweet and neutral, can induce diuresis and reduce edema, can purge heat and calm liver, and has excellent diuretic effect. The chlorella pyrenoidosa has the functions of clearing away heat and toxic materials, removing acid and descending turbidity, so that the arthralgia syndrome can achieve the effects of tonifying qi, invigorating spleen and promoting diuresis, dispelling wind and dissipating heat, and removing acid and descending turbidity from meridians to viscera. The 4 components have synergistic interaction, the effect of reducing the uric acid is obviously superior to the effect of reducing the uric acid by combining a single raw material or two or three raw materials, the effect of effectively reducing the uric acid is achieved, and no toxic or side effect is caused.
4. The invention adds a plurality of vitamins, and the addition of the vitamins interacts with other components, thereby quickening the dissolution speed of the active ingredients of the medicine and leading the medicine composition to have good performance.
Detailed Description
The present invention is further illustrated by the following examples, which are not to be construed as limiting the invention.
It should be noted that the embodiments and features of the embodiments may be combined with each other without conflict.
Example 1
An active polysaccharide-containing medicament with the effect of reducing uric acid comprises the following components in parts by weight: 8 parts of marine fish oligopeptide powder, 5 parts of taxus chinensis polysaccharide, 7 parts of pawpaw, 6 parts of pit viper, 7 parts of coix seed, 11 parts of celery powder, 11 parts of burdock root powder, 1 part of corn stigma powder, 3 parts of globulina powder, 6 parts of vitamin A, 11 parts of flavoring agent and 5 parts of phellinus igniarius.
The preparation method of the medicine containing active polysaccharide comprises the following steps:
s1, weighing the pawpaw and the pit viper according to the weight parts, adding 12 times of water, heating and extracting for 2 times, each time for 2 hours, filtering, combining the filtrates, and concentrating the filtrate to a clear paste with a relative density of 1.2 measured at 65 ℃; weighing the coix seeds according to the parts by weight, crushing the coix seeds into fine powder, and sieving the fine powder by a 60-mesh sieve;
s2, weighing the marine fish oligopeptide powder, the taxus chinensis polysaccharide, the celery powder, the burdock root powder, the corn stigma powder, the globulina powder, the vitamins, the edible auxiliary materials and the phellinus igniarius according to the parts by weight, adding the clear paste prepared in the step S1 and the coix seed powder, and uniformly mixing to prepare the active polysaccharide-containing medicine tablet.
Example 2
An active polysaccharide-containing medicament with the effect of reducing uric acid comprises the following components in parts by weight: 11 parts of marine fish oligopeptide powder, 8 parts of taxus chinensis polysaccharide, 12 parts of pawpaw, 9 parts of pit viper, 12 parts of coix seed, 18 parts of celery powder, 16 parts of burdock root powder, 7 parts of corn stigma powder, 10 parts of globulina powder, 111 parts of vitamin B, 25 parts of excipient and 9 parts of phellinus igniarius.
The preparation method of the medicine containing active polysaccharide comprises the following steps:
s1, weighing the pawpaw and the pit viper according to the weight parts, adding 13 times of water, heating and extracting for 3 times, each time for 2.5 hours, filtering, combining the filtrates, and concentrating the filtrate to a clear paste with a relative density of 1.3 measured at 70 ℃; weighing the coix seeds according to the parts by weight, crushing the coix seeds into fine powder, and sieving the fine powder by a sieve of 80 meshes;
s2, weighing the marine fish oligopeptide powder, the taxus chinensis polysaccharide, the celery powder, the burdock root powder, the corn stigma powder, the globulina powder, the vitamins, the edible auxiliary materials and the phellinus igniarius according to the parts by weight, adding the clear paste prepared in the step S1 and the coix seed powder, and uniformly mixing to prepare the active polysaccharide-containing medicine capsule.
Example 3
An active polysaccharide-containing medicament with the effect of reducing uric acid comprises the following components in parts by weight: 15 parts of marine fish oligopeptide powder, 12 parts of taxus chinensis polysaccharide, 15 parts of pawpaw, 11 parts of pit viper, 13 parts of coix seed, 20 parts of celery powder, 19 parts of burdock root powder, 15 parts of corn stigma powder, 16 parts of globulina powder, 19 parts of nicotinic acid, 30 parts of stabilizer and 15 parts of phellinus igniarius.
The preparation method of the medicine containing active polysaccharide comprises the following steps:
s1, weighing the pawpaw and the pit viper according to the weight parts, adding 15 times of water, heating and extracting for 3 times, each time for 3 hours, filtering, combining the filtrates, and concentrating the filtrate to a clear paste with a relative density of 1.4 measured at 75 ℃; weighing the coix seeds according to the parts by weight, crushing the coix seeds into fine powder, and sieving the fine powder by a sieve of 90 meshes;
s2, weighing the marine fish oligopeptide powder, the taxus chinensis polysaccharide, the celery powder, the burdock root powder, the corn stigma powder, the globulina powder, the vitamins, the edible auxiliary materials and the phellinus igniarius according to the parts by weight, adding the clear paste prepared in the step S1 and the coix seed powder, and uniformly mixing to prepare the active polysaccharide-containing medicinal granule.
Application example
Patient data: 150 patients, 100 males of which were aged between 35-75 years; 50 women, with the age distribution of 35-75 years.
Diagnostic criteria: the patient has arthralgia, attacks at night and is difficult to fall asleep; elevated blood uric acid levels, above 6.0mg/dL for men and 5.0mg/dL for women; has a tophus.
The taking method comprises the following steps: the preparation containing active polysaccharide is administered 3 times a day, 2 tablets or 2 tablets each time, one time in the morning, one time in the evening, and 7 weeks continuously.
Efficacy evaluation criteria: and (3) curing: the laboratory checks that the blood uric acid value is normal, the arthralgia symptom disappears, and the tophus is removed; improvement: the reduction of blood uric acid value, the resolution of joint swelling and pain and the obvious reduction of tophus are detected in a laboratory; and (4) invalidation: the blood uric acid value and symptoms are unchanged in laboratory examination, and the tophus is unchanged. The test results are shown in table 1:
TABLE 1
Figure BDA0002683854630000051
The data in table 1 show that the active polysaccharide-containing medicament provided by the invention is prepared by reasonably proportioning and scientifically matching the raw materials, the components play a synergistic effect, and edible auxiliary materials are reasonably matched, so that the active polysaccharide-containing medicament can be prepared into health care products, foods or medicaments such as tablets, capsules, powder, pills or granules with an obvious effect of reducing uric acid and no side effect, and the effective rate of reducing uric acid can reach more than 97.3% after a patient takes the active polysaccharide-containing medicament for 7 weeks.
While the invention has been described with reference to a preferred embodiment, it will be understood by those skilled in the art that various changes in form and detail may be made therein without departing from the spirit and scope of the invention.

Claims (8)

1. The active polysaccharide-containing medicine with the effect of reducing the uric acid is characterized by comprising the following components in parts by weight: 8-15 parts of marine fish oligopeptide powder, 5-12 parts of taxus chinensis polysaccharide, 7-15 parts of pawpaw, 6-11 parts of pit viper, 7-13 parts of coix seed, 11-20 parts of celery powder, 11-19 parts of burdock root powder, 1-15 parts of corn stigma powder, 3-16 parts of egg white chlorella powder, 6-19 parts of vitamin, 11-30 parts of edible auxiliary material and 5-15 parts of phellinus igniarius.
2. The active polysaccharide containing drug with the effect of reducing uric acid according to claim 1, wherein the active polysaccharide containing drug comprises the following components in parts by weight: 10-13 parts of marine fish oligopeptide powder, 7-10 parts of taxus chinensis polysaccharide, 9-14 parts of pawpaw, 8-10 parts of pit viper, 8-11 parts of coix seed, 17-20 parts of celery powder, 16-18 parts of burdock root powder, 13-15 parts of corn stigma powder, 14-16 parts of chlorella pyrenoidosa powder, 10-15 parts of vitamin, 12-29 parts of edible auxiliary materials and 8-12 parts of phellinus igniarius.
3. The active polysaccharide medicine containing high uric acid lowering effect as claimed in claim 1, wherein the vitamin is one or more of vitamin A, vitamin D, vitamin E, vitamin C, vitamin B1, vitamin B2, vitamin B6, vitamin B12, nicotinic acid, folic acid, pantothenic acid, choline and nicotinamide.
4. The active polysaccharide-containing medicine with the effect of reducing uric acid according to claim 1, wherein the edible auxiliary materials are one or more of an excipient, a stabilizer, a flavoring agent and a color fixative.
5. The process for the preparation of a medicament containing an active polysaccharide according to any one of claims 1 to 4, comprising the steps of:
s1, weighing the pawpaw and the pit viper according to the weight parts, adding 12-15 times of water, heating and extracting for several times, filtering, combining the filtrates, and concentrating the filtrate to a clear paste with the relative density of 1.2-1.4 measured at 65-75 ℃; weighing the coix seeds according to the parts by weight, crushing the coix seeds into fine powder, and sieving the fine powder by a sieve of 60-90 meshes;
s2, weighing the marine fish oligopeptide powder, the taxus chinensis polysaccharide, the celery powder, the burdock root powder, the corn stigma powder, the globulina powder, the vitamins, the edible auxiliary materials and the phellinus igniarius according to the parts by weight, adding the clear paste prepared in the step S1 and the coix seed powder, and uniformly mixing to prepare the active polysaccharide-containing pharmaceutical preparation.
6. The process of claim 5, wherein the extraction under heating in S1 is performed 2-3 times for 2-3 hours each time.
7. The method for preparing a drug containing active polysaccharide according to claim 1, wherein in S2, the formulation of the drug containing active polysaccharide is tablet, capsule, powder, pill or granule.
8. Use of the active polysaccharide containing drug according to any one of claims 1-4 for the preparation of a uric acid lowering health product, food or medicament.
CN202010970484.8A 2020-09-15 2020-09-15 Medicine containing active polysaccharide with effect of reducing uric acid and preparation method thereof Pending CN112023019A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010970484.8A CN112023019A (en) 2020-09-15 2020-09-15 Medicine containing active polysaccharide with effect of reducing uric acid and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010970484.8A CN112023019A (en) 2020-09-15 2020-09-15 Medicine containing active polysaccharide with effect of reducing uric acid and preparation method thereof

Publications (1)

Publication Number Publication Date
CN112023019A true CN112023019A (en) 2020-12-04

Family

ID=73590350

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010970484.8A Pending CN112023019A (en) 2020-09-15 2020-09-15 Medicine containing active polysaccharide with effect of reducing uric acid and preparation method thereof

Country Status (1)

Country Link
CN (1) CN112023019A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114010755A (en) * 2021-12-15 2022-02-08 本元大健康科技产业(广东)有限公司 Preparation for controlling uric acid and preparation method thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1572318A (en) * 2003-05-30 2005-02-02 利统股份有限公司 Composition containing dipeptide of histidine and alanine for reducing uric acid
KR101346281B1 (en) * 2013-08-20 2013-12-31 강영효 Compositions for preventing, improving or treating gout, containing extracts of twenty nine medicine plants as active ingredient
CN103622019A (en) * 2013-12-02 2014-03-12 广西健丰药业有限公司 Traditional Chinese medicine composition capable of reducing blood lipid and uric acid
US20170014467A1 (en) * 2015-07-14 2017-01-19 Infinitus (China) Company Ltd. Composition and the use thereof
CN109400750A (en) * 2018-12-05 2019-03-01 吉林浩泰健康产业发展有限公司 A kind of preparation method of avenabeta glucosan
CN110511290A (en) * 2018-05-07 2019-11-29 武汉紫杉红技术开发有限公司 A kind of preparation method and applications of the yew amylose with drop high lithemia effect

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1572318A (en) * 2003-05-30 2005-02-02 利统股份有限公司 Composition containing dipeptide of histidine and alanine for reducing uric acid
KR101346281B1 (en) * 2013-08-20 2013-12-31 강영효 Compositions for preventing, improving or treating gout, containing extracts of twenty nine medicine plants as active ingredient
CN103622019A (en) * 2013-12-02 2014-03-12 广西健丰药业有限公司 Traditional Chinese medicine composition capable of reducing blood lipid and uric acid
US20170014467A1 (en) * 2015-07-14 2017-01-19 Infinitus (China) Company Ltd. Composition and the use thereof
CN110511290A (en) * 2018-05-07 2019-11-29 武汉紫杉红技术开发有限公司 A kind of preparation method and applications of the yew amylose with drop high lithemia effect
CN109400750A (en) * 2018-12-05 2019-03-01 吉林浩泰健康产业发展有限公司 A kind of preparation method of avenabeta glucosan

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
陈光亮 等: "治疗痛风和高尿酸血症药物研究进展", 《中国临床药理学与治疗学 》 *
陈康林: "《药用真菌肿瘤学 生物免疫化疗治肿瘤》", 30 June 2017, 中医古籍出版社 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114010755A (en) * 2021-12-15 2022-02-08 本元大健康科技产业(广东)有限公司 Preparation for controlling uric acid and preparation method thereof

Similar Documents

Publication Publication Date Title
JP5588351B2 (en) Formulation containing rosehip extract
CN106975069B (en) Liver-protecting composition and preparation method thereof
US20140044811A1 (en) Method and process for relieving or preventing symptoms
JP6345243B2 (en) Enbu fermented food or beverage composition
JP5685752B2 (en) Blood flow promoting agent
Djarot et al. Formulation and production of granule from Annona muricata fruit juice as antihypertensive instant drink
CN102178217B (en) Konjac-flour-containing mixture and preparation method thereof
CN104398561A (en) Medicinal and edible variety composition for preventing and treating alcoholic liver diseases, and its preparation method
CN112023019A (en) Medicine containing active polysaccharide with effect of reducing uric acid and preparation method thereof
EP1583547B1 (en) Anti-obesity ingredients from medicinal plants and their composition
CN105920198B (en) Cell wall-broken micropowder with blood replenishing effect and preparation method thereof
CN111513325A (en) Food for reducing uric acid
JP7180839B2 (en) Composition containing spice, bonito extract and kelp extract
JP7176813B2 (en) Composition for improving fatigue
CN106690121A (en) Trepang, hippophae rhamnoides fruit, cordyceps militaris and selenium preparation and preparation technology thereof
WO2005094858A1 (en) Antidiabetic composition
KR101910013B1 (en) A composition for improving, preventing and treating of pain comprising herb extract
CN104799292A (en) Intestine-moistening and bowels-relaxing food and preparation method thereof
KR101069844B1 (en) A composition for the prevention and treatment of edema or dermatitis containing Angelica decursiva extract or fraction thereof as an active ingredient
CN107753775B (en) Chrysanthemum composition and application thereof
KR101528557B1 (en) A pharmaceutical composition comprising fermented Eastern prickly pear
KR101080927B1 (en) An anti-inflammatory composition for the prevention and treatment of edema or a variety of inflammations containing Koelreuteria paniculata extract or fraction thereof as an active ingredient
JP6698034B2 (en) Oral composition for improving systemic symptoms such as chills
CN110339229B (en) Viscosity-reducing and blood-clearing composition and application thereof
KR20190101632A (en) Anti-inflammatory composition containing medicinal herbs

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20201204

RJ01 Rejection of invention patent application after publication